Six of the world’s top translational health research centers have come together to form a new Global Alliance of Leading Drug Discovery and Development Centres. This coalition aims to strengthen the international academic and/or not-for-profit drug development and commercialization network to improve the rate at which academic research is translated into new medicines.
The founding organizations are The Centre for Drug Research and Development, Canada; Lead Discovery Center, Germany; The Scripps Research Institute, Scripps Florida, United States; The Center for Drug Design and Discovery, KU Leuven Research & Development, Belgium; Medical Research Council Technology, United Kingdom; and Cancer Research Technology, United Kingdom.
All member organizations are fully integrated translational centers capable of professionally advancing drug discovery projects along the value chain from idea to drug candidate with proof-of-concept. They represent close to 400 experienced drug developers collaborating with tens of thousands of academic scientists globally on over 165 innovative therapeutic projects.
Through this alliance, member organizations will collaborate on mutually beneficial projects, share best practices, expertise and resources, and develop common standards and performance measurements.
“This will allow every one of us to be more efficient and to allign or adapt our research efforts if needed,” Patrick Chaltin, Ph.D., managing director of The Centre for Drug Design and Discovery. “This alliance is a major step forward in further bridging the gap between academic innovative research and the needs of the pharmaceutical industry to the benefit of patients.”